title: Immunotherapy in gastric cancer.
abstract: Gastric cancer is the second most common of cancer-related deaths worldwide. In the majority of cases gastric cancer is advanced at diagnosis and although medical and surgical treatments have improved, survival rates remain poor. Cancer immunotherapy has emerged as a powerful and promising clinical approach for treatment of cancer and has shown major success in breast cancer, prostate cancer and melanoma. Here, we provide an overview of concepts of modern cancer immunotherapy including the theory, current approaches, remaining hurdles to be overcome, and the future prospect of cancer immunotherapy in the treatment of gastric cancer. Adaptive cell therapies, cancer vaccines, gene therapies, monoclonal antibody therapies have all been used with some initial successes in gastric cancer. However, to date the results in gastric cancer have been disappointing as current approaches often do not stimulate immunity efficiently allowing tumors continue to grow despite the presence of a measurable immune response. Here, we discuss the identification of targets for immunotherapy and the role of biomarkers in prospectively identifying appropriate subjects or immunotherapy. We also discuss the molecular mechanisms by which tumor cells escape host immunosurveillance and produce an immunosuppressive tumor microenvironment. We show how advances have provided tools for overcoming the mechanisms of immunosuppression including the use of monoclonal antibodies to block negative regulators normally expressed on the surface of T cells which limit activation and proliferation of cytotoxic T cells. Immunotherapy has greatly improved and is becoming an important factor in such fields as medical care and welfare for human being. Progress has been rapid ensuring that the future of immunotherapy for gastric cancer is bright.
authors.affiliation: Satoko Matsueda, Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka 830-0011, Japan.
authors.forename: Satoko
authors.initials: S
authors.lastname: Matsueda
authors.affiliation: Satoko Matsueda, Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Fukuoka 830-0011, Japan.
authors.forename: David Y
authors.initials: DY
authors.lastname: Graham
mesh_terms: D000818:Animals; D000906:Antibodies / Q000737:chemistry; D000911:Antibodies, Monoclonal / Q000737:chemistry; D015415:Biomarkers / Q000737:chemistry; D019496:Cancer Vaccines / Q000627:therapeutic use; D049109:Cell Proliferation; D006801:Humans; D007166:Immunosuppressive Agents / Q000737:chemistry; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive / Q000379:methods; D007249:Inflammation; D008213:Lymphocyte Activation; D012313:RNA / Q000737:chemistry; D013274:Stomach Neoplasms / Q000276:immunology* / Q000628:therapy*; D013601:T-Lymphocytes / Q000166:cytology
chemical_list: D000906:Antibodies; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D019496:Cancer Vaccines; D007166:Immunosuppressive Agents; D012313:RNA
keywords: Adoptive cell therapy; Antibody therapy; Cancer vaccine; Gastric cancer; Immune checkpoint; Immune escape; Predictive biomarker